Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CFO resigned
Acq. announced
CC transcript
Director departure
AVANIR PHARMACEUTICALS, INC. (AVNR) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/11/2015 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2015 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 0% stake in AVANIR PHARMACEUTICALS INC
02/09/2015 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 12.1% stake in AVANIR PHARMACEUTICALS INC
01/26/2015 SC 13G/A BlackRock Inc. reports a 7.5% stake in AVANIR PHARMACEUTICALS INC
01/13/2015 8-K Quarterly results
01/13/2015 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
01/12/2015 SC 13G/A FMR LLC reports a 2.4% stake in AVANIR PHARMACEUTICALS
01/06/2015 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
01/05/2015 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
12/31/2014 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
12/22/2014 4 Form 4 - Statement of changes in beneficial ownership of securities
12/18/2014 4 OCAMPO CHRISTINE (Vice President, Finance) has filed a Form 4 on AVANIR PHARMACEUTICALS, INC.
12/18/2014 4 Katkin Keith (President and CEO) has filed a Form 4 on AVANIR PHARMACEUTICALS, INC.
Txns: Sold 20,000 shares @ $16.95, valued at $339k
Sold 195,160 shares @ $16.95, valued at $3.3M
Sold 62,520 shares @ $16.93, valued at $1.1M
Exercised 55,960 options to buy @ $1.29, valued at $72.2k
Exercised 139,200 options to buy @ $1.74, valued at $242.2k
12/12/2014 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
12/12/2014 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
12/11/2014 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
12/10/2014 10-K Annual Report for the period ended September 30, 2014
12/10/2014 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
12/02/2014 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
12/02/2014 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
12/02/2014 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Agreement and Plan of Merger, by and among Otsuka Pharmaceutical Co., Ltd., Bigarade Corporation and Avanir Pharmaceuticals, Inc",
"AVANIR PHARMACEUTICALS TO BE ACQUIRED BY OTSUKA PHARMACEUTICAL FOR $3.5 BILLION"
12/02/2014 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
11/28/2014 4 PALEKAR ROHAN (SVP & Chief Commercial Officer) has filed a Form 4 on AVANIR PHARMACEUTICALS, INC.
Txns: Sold 15,000 shares @ $15, valued at $225k
Exercised 15,000 options to buy @ $3.38, valued at $50.7k
11/26/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Avanir Pharmaceuticals Receives Complete Response Letter from FDA on AVP-825 NDA"
11/12/2014 4 PALEKAR ROHAN (SVP & Chief Commercial Officer) has filed a Form 4 on AVANIR PHARMACEUTICALS, INC.
Txns: Granted 59,231 shares @ $0
Granted 34,825 shares @ $0
11/12/2014 4 Siffert Joao MD (SVP, R&D) has filed a Form 4 on AVANIR PHARMACEUTICALS, INC.
11/12/2014 4 Katkin Keith (President and CEO) has filed a Form 4 on AVANIR PHARMACEUTICALS, INC.
Txns: Granted 220,563 shares @ $0
Granted 140,611 shares @ $0
11/12/2014 4 OCAMPO CHRISTINE (Vice President, Finance) has filed a Form 4 on AVANIR PHARMACEUTICALS, INC.
11/12/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/10/2014 SC 13G/A BAKER BROS. ADVISORS LP reports a 17% stake in Avanir Pharmaceuticals, Inc.
11/10/2014 SC 13G/A FMR LLC reports a 10.8% stake in AVANIR PHARMACEUTICALS
11/07/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Avanir Pharmaceuticals Announces Preliminary Feedback from the FDA on AVP-825 for the Acute Treatment of Migraine"
10/24/2014 4 Siffert Joao MD (SVP, R&D) has filed a Form 4 on AVANIR PHARMACEUTICALS, INC.
10/24/2014 4 Katkin Keith (President and CEO) has filed a Form 4 on AVANIR PHARMACEUTICALS, INC.
Txns: Sold 27,567 shares @ $11.76, valued at $324.2k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy